Work

An open-label single-center investigator-initiated exploratory clinical study in patients with refractory or recurrent solid tumors using SBRT as “in situ vaccination”: R-ISV-FOLactis trial.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.23_suppl.44

Authors: Rutian Li, Juanjuan Dai, Jie Shen, Xiaolu Wang, Jinfeng Bao, Xiaofeng Chang, Yingling Zhou, Wu Sun, Qin Wang, Shiyao Du, Siyi Tan, Junmeng Zhu, Xia Zhou, Qin Liu, Lijing Zhu, Baorui Liu

Institutions: Nanjing Drum Tower Hospital, Nanjing University, Nanjing University of Chinese Medicine, Nanjing Medical University

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Natural Science Foundation of China

OpenAlex ID: W4401514460

Cites:

Cited by:

Related to: 10